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Abstract
The bisulfite genomic sequencing protocol is a widely used method for analyzing DNA methylation. It relies
on the deamination of unmethylated cytosine residues to uracil; however, its high rates of DNA degradation
and incomplete cytosine to uracil conversion often lead to failed experiments, uninformative results, and false
positives. Here, we report the addition of a single-step multiple restriction enzyme digestion (MRED)
designed to differentially digest polymerase chain reaction products amplified from unconverted DNA while
leaving those of converted DNA intact. We show that for our model system, RARB2 P2 promoter, use of
MRED increased informative sequencings ninefold, and MRED did not alter the clonal representation in
one fully methylated cell line, H-596, treated or not with 5-azadeoxycytidine, a methylation inhibitor.
We believe that this method may easily be adapted for analyzing other genes and provide guidelines for
selecting the most appropriate MRED restriction enzymes.
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1. Introduction
The bisulfite genomic sequencing (BGS) protocol (1, 2)i sa
methodofchoiceforanalyzingDNAmethylationatthenucleotide
level. Sodium bisulfite is used to convert unmethylated cytosine
residuestouracilresiduesinsingle-strandedDNA.Inparticular,bi-
sulfite conversion consists of three sequential chemical reactions:
sulfonation of cytosine to cytosine-6-sulfonate, deamination to
uracil-6-sulfonate, and desulfonation to uracil. However, since 5-
methylcytosine residues are nonreactive, they remain intact. The
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99bisulfite-converted DNA is then amplified with specific primers
designed for converted DNA, and purified polymerase chain reac-
tion (PCR) products, which are usually subcloned, are sequenced.
Bisulfite conversion is so powerful that it has been paired with
numeroustechniquesotherthantraditionalsequencing,including:
methylation-specific PCR (3), combined bisulfite restriction en-
zyme analysis (4), methylation-sensitive single nucleotide primer
extension (5), methylation-sensitive single-strand conformation
analysis (6), MethyLight (7), oligonucleotide microarray methods
(8), denaturing high-performance liquid chromatography with bi-
sulfite genomic sequencing (9), pyrosequencing methylation anal-
ysis (10), and methylation-sensitive high-resolution melting-curve
analysis (11), among others (see (12) for a review). In addition,
many methylation analysis kits are also commercially available.
Unfortunately, high rates of DNA degradation and incom-
plete conversion reactions often lead to decreased efficiency of
the assay. Many attempts have been made to minimize template
degradation and/or maximize cytosine conversion (13–19), but
overall, the bisulfite conversion protocol has remained un-
changed, and no other high resolution or positive display methyl-
ation analysis protocol exists. As a result, the BGS protocol, as
well as any technique paired with the bisulfite conversion reaction
(and, hence, founded on the assumption that conversion is com-
plete) often generate few or no informative results.
In our studies of the RARB2 P2 promoter (20), we found
that incomplete conversion was an insurmountable challenge even
after modifying the protocol in numerous ways. We, therefore,
aimed to circumvent these issues altogether by depleting the
PCR populations of products amplified from partially converted
or unconverted DNA using a multiple restriction enzyme diges-
tion (MRED) approach. We found that informative sequencings
were increased ninefold using it. We believe that this method
may easily be adapted for analyzing the detailed methylation sta-
tus of other genes presenting incomplete cytosine to uracil con-
version, and we provide guidelines for selecting the most
appropriate restriction enzymes (REs).
2. Materials
and Methods
2.1. Cell Culture
and Genomic DNA
Extraction
2.1.1. Cell-Line Provenance Twenty-one cell lines were cultured. CALU-1, SK-MES, CACO-
2, COLO-201, COLO-205, HCT-15, and LS-180 were
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MD). The CALU-1 daughter cell lines, C-19 and C-59, are
RARB2-transfectants that were established in our laboratory
(21). MM-1 was also established in our laboratory (6). NCI-
H23, NCI-H82, NCI-H125, NCI-H157, NCI-H520, and
NCI-H596 were supplied by Dr. Adi Gazdar (NCI, NIH,
Bethesda, MD). NBE-E6E7 (22) was provided by Dr. Jean Viallet
(Gemin X Biotechnologies Inc., Montreal, Québec). SW 1222
was given to us by Dr. Clifford Stanners (McGill University,
Montreal,Québec).Qu-DBwasprovidedbyDr.BarbaraCampling
(Queen’s University, Kingston, Ontario). T47D, MDA-MB-231
(MB-231), ZR-75B, and HS-578T were kindly provided by Dr.
Morag Park (McGill University, Montreal, Québec).
2.1.2. Cell Culture CALU-1, CACO-2, SW-1222, and LS-180 were grown in
α-MEM medium (Invitrogen, Carlsbad, CA) supplemented with
10% heat-inactivated fetal calf serum (FCS; Wisent Bioproducts,
Saint-Jean-Baptiste de Rouville, Québec). NBE-E6E7 was grown
in keratinocyte-serum free medium (Invitrogen), supplemented
with 50 µg/ml bovine pituitary extract, and 5 ng/ml recombi-
nant human epidermal growth factor (Invitrogen). All other cells
were grown in RPMI-1640 medium (Invitrogen) supplemented
either with 5% (SK-MES, NCI-H23, NCI-H125, NCI-H520,
Qu-DB, and HS-578T) or 10% FCS (NCI-H82, NCI-H157,
MM-1, T47D, MDA-MB-231, ZR-75B, COLO-201, COLO-
205, and HCT-15). Where indicated, cells were treated with
1 µM 5-azadeoxycytidine.
2.1.3. Genomic DNA
Extraction
Genomic DNA was extracted using the standard phenol-chloro-
form technique followed by proteinase K treatment to ensure
complete protein removal (23). DNA was then digested with
the PstI RE (New England BioLabs, Ipswich, MA) according to
the supplier′s directives to shorten the fragment (2.95 kb) con-
taining the target RARB2 P2 promoter sequence investigated
(541 bp; Fig. 1), thereby reducing the possibility for regional
double-strand formation (24). PstI was the only RE available for
the sequence under analysis.
2.2. Bisulfite
Conversion
2.2.1. Bisulfite Conversion Multiple DNA samples of each cell line, 1–2 µg each, were treated
with bisulfite as per the BGS protocol (1), with minor modifica-
tions. Briefly, PstI-digested genomic DNA (1–2 μg) was precipi-
tated and resuspended in 25 μl distilled water. DNA was
denatured with 0.3 N NaOH at 37°C for 15 min. Fifteen micro-
liters of freshly prepared 10 mM hydroquinone (Sigma–Aldrich
Canada Ltd., Oakville, Ontario) was added to the tubes while
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minimal aeration. Two hundred fifty microliters of freshly pre-
pared 3.6 M sodium bisulfite (Sigma–Aldrich), pH 5.0, was added
to the tubes while at 37°C, and solutions were again carefully
mixed by inversion with minimal aeration. Reaction volumes were
overlaid with mineral oil and incubated at 55°C for 16 h in the
dark. Aqueous phases were transferred to new tubes and desalted
JP5       HhaI
ggagtggaaaaatacataagttataaggaaTTTAACAGACAGAAAGGCGC
                                                1  
 
ACAGAGGAATTTAAAGTGTGGGCTGGGGGGCGAGGCGGTGGGCGGGAGGC
                               2    3      4     5
      HhaI                  AluIDdeI        
GAGCGGGCGCAGGCGGAACACCGTTTTCCAAGCTAAGCCGCCGCAAATAA
    6   7     8       9               10 11       
 
AAAGGCGTAAAGGGAGAGAAGTTGGTGCTCAACGTGAGCCAGGAGCAGCG
     12                         13              14
  HpaII 
TCCCGGCTCCTCCCCTGCTCATTTTAAAAGCACTTCTTGTATTGTTTTTA
   15 
                        HpaII   HhaI 
AGGTGAGAAATAGGAAAGAAAACGCCGGCTTGTGCGCTCGCTGCCTGCCT
                      16 17       18  19          
                                        AluI 
CTCTGGCTGTCTGCTTTTGCAGGGCTGCTGGGAGTTTTTAAGCTCTGTGA
                  
                  CREB         AP-1-like 
GAATCCTGGGAGTTGGTGATGTCAGACTAGTTGGGTCATTTGAAGGTTAG
    AvaI                
HpaII                      RARE            TATA BOX 
CAGCCCGGGTAGGGTTCACCGAAAGTTCACTCGCATATATTAGGCAATTC
     20            21          22   
               AluI 
AATCTTTCATTCTGTGTGACAGAAGTAGTAGGAAGTGAGCTGTTCAGAGG
                    
CAGGAGGGTCTattctttgccaaaggggggaccagaattccCCCATGCGA
                         JP7 
GCTGTTTGAGGACTGGGATGCCGAGAACGCGAGCGATCCGAGCAGGGTTT
GTCTGGGCACCGTCGGGGTAGGATCCGGAACGCATTCGGAAGGCTTTTTG
CAAGCATTTACTTGGAAGGAGAACTTGGGATCTTTCTGGGAACCCCCCGC
CCCGGCTGGATTGGCCGAGCAAGCCTGGAAAATGGTAAATGATCATTTGG
ATCAATTACAGGCTTTTAGCTGGCTTGTCTGTCATAATTCATGATTCGGG
GCTGGGAAAAAGACCAACAGCCTACGTGCCAAAAAAGGGGCagagtttga
tggagttgggtggacttttct                       JP6
+1
Fig. 1. RARB2 sequence under analysis. A Unconverted sequence; B
converted sequence (all non-CpG-cytosines have been replaced with
thymidines). The 541 bp sequence analyzed is comprised between
oligonucleotides JP5 and JP7. CG = CpG dinucleotide under investi-
gation (n=22); T=non-CpG-cytosine converted to thymidine following
bisulfite treatment (n=82); boxes promoter elements; gray-shaded se-
quences RE sites (please note that these sites are absent in the con-
verted sequence); +1 transcription start site. Direct repeats of the
RARE are indicated. The oligonucleotide sequences are underlined and
are designed for converted DNA.
102 J.J. Pappas et al.with Wizard Magic Miniprep DNA purification resins (Promega,
Madison, WI). DNA was eluted with 120 µl distilled water and
residual alcohol was removed using speedvac centrifugation.
Ten microliters 3N NaOH was added to the remaining 100 µl
and allowed to incubate for 15 min at 37°C. DNA was precipitat-
ed with 33 µl 10 M sodium acetate pH 7.8 and 300 µl chilled eth-
anol using glycogen as a carrier in an ice-water bath for 10 min
a n dt h e nc e n t r i f u g e da t1 3 , 0 0 0 × g for 60 min. The precipitate
was resuspended in 100 μl TE pH 8.0.
2.2.2. PCR Amplification A 541-bp sequence containing 22 CpG dinucleotides (Fig. 1A)
was identified within the human RARB P2 promoter (20).
PCR amplification consisted of two rounds of amplification:
round 1 primers consisted of the upper primer JP5 (5′-
GGAGTGGAAAAATATATAAGTTATAAGGAA-3′)a n dt h e
l o w e rp r i m e rJ P 6( 5 ′-AAAAAAATCCACCCAACTCCAT
            JP5 
ggagtggaaaaatatataagttataaggaaTTTAATAGATAGAAAGGCGT
                                                1 
 
ATAGAGGAATTTAAAGTGTGGGTTGGGGGGCGAGGCGGTGGGCGGGAGGC
                               2    3      4     5
 
GAGCGGGCGTAGGCGGAATATCGTTTTTTAAGTTAAGTCGTCGTAAATAA
    6   7     8       9               10 11 
 
AAAGGCGTAAAGGGAGAGAAGTTGGTGTTTAACGTGAGTTAGGAGTAGCG
     12                         13              14
 
TTTCGGTTTTTTTTTTGTTTATTTTAAAAGTATTTTTTGTATTGTTTTTA
   15     
 
AGGTGAGAAATAGGAAAGAAAACGTCGGTTTGTGCGTTCGTTGTTTGTTT
                      16 17       18  19  
 
TTTTGGTTGTTTGTTTTTGTAGGGTTGTTGGGAGTTTTTAAGTTTTGTGA
 
                  CREB         AP-1-like 
GAATTTTGGGAGTTGGTGATGTTAGATTAGTTGGGTTATTTGAAGGTTAG
 
                   RARE            TATA BOX 
TAGTTCGGGTAGGGTTTATCGAAAGTTTATTCGTATATATTAGGTAATTT
     20            21           22 
 
AATTTTTTATTTTGTGTGATAGAAGTAGTAGGAAGTGAGTTGTTTAGAGG
                     
TAGGAGGGTTTattttttgttaaaggggggattagaattttTTTATGCGA
                         JP7 
GTTGTTTGAGGATTGGGATGTCGAGAACGCGAGCGATTCGAGTAGGGTTT
GTTTGGGTATCGTCGGGGTAGGATTCGGAACGTATTCGGAAGGTTTTTTG
TAAGTATTTATTTGGAAGGAGAATTTGGGATTTTTTTGGGAATTTTTCGT
TTCGGTTGGATTGGTCGAGTAAGTTTGGAAAATGGTAAATGATTATTTGG
ATTAATTATAGGTTTTTAGTTGGTTTGTTTGTTATAATTTATGATTCGGG
GTTGGGAAAAAGATTAATAGTTTACGTGTTAAAAAAGGGGTagagtttga
tggagttgggtggattttttt                       JP6 
+1
Fig. 1. (continued).
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J P 5a n dt h el o w e rp r i m e rJ P 7( 5 ′-AAAATTCTA
ATCCCCCCTTTAACAAAAAAT-3′). Cycling conditions
were: 94°C/4 min×1 cycle; 94°C/1 min, 61°C/2 min,
72°C/2 min×5 cycles; 94°C/1 min, 61°C/1.5 min, 72°C/
1.5–2 min×25 cycles; 72°C/5 min×1 cycle. Primers were
designed following the guidelines found in (25). In particular,
they were designed not to contain CpG dinucleotides so that
PCR amplifications were not biased according to methylation
status. The minimum number of non-CpG-cytosines available
for measuring the rate of cytosine to uracil conversion, for
quality control assessment, is 74. This does not include the
one non-CpG-cytosine within the region complementary to
JP5 and the seven non-CpG-cytosines within the region com-
plementary to JP7 (see section 2.3.2, Special Considerations).
2.3. MRED
2.3.1. Restriction Enzyme
Selection
The original (Fig. 1A) and converted (Fig. 1B) sequences were en-
tered into NEBcutter V.2 at http://tools.neb.com/NEBcutter2/
index.php (New England BioLabs), and RE maps and lists were
made. Potential MRED isoschizomers were screened based on the
following criteria: (1) RE sites should selectively cut unconverted
DNA while leaving converted DNA intact; (2) RE sites may or
may not contain CpG-cytosines but should contain at least one
non-CpG-cytosine; (3) if RE sites do not contain at least one non-
CpG-cytosine,thenREsitesshouldnotcontaineitherofthefollow-
ing: (a) a CpG-cytosine, (b) a 3′-C if immediately followed by a G
within the downstream sequence, or (c) a 5′-G if immediately pre-
ceded by a C within the upstream sequence (for a summary of these
criteria, see Table 1).
2.3.2. Special
Considerations
(1) Since primers can anneal to DNA sequences with less than
perfect complementarity and since this may potentially involve
primer adenines annealing to unconverted non-CpG-cytosines,
we omitted all MREDenzymes with sites within primer sequences.
Table 1
Guidelines for choosing (MRED) restriction enzymes
1 The RE site must contain at least one non-CpG-cytosine
2 The RE site must be abolished following cytosine to uracil conversion
3 The most 5′ and 3′ nucleotides of the sequence must not form CpG dinucleotides with upstream or
downstream sequences respectively
4 The RE site preferably does not have a site within the primer sequences
5 The RE site may be cut with a methylation-sensitive RE, since PCR products are not methylated
104 J.J. Pappas et al.We reasoned that not omiting them might incorporate some
incompletely converted molecules. (2) It may be noteworthy to
clarify that methylation-sensitive RE may indeed be used since
the DNA being cleaved is synthesized in vitro (via PCR) and,
hence, not methylated. (3) The five RE we chose (AluI, AvaI,
DdeI, HhaI, and HpaII) have a total of 11 sites within the target
sequence, and each RE contains one non-CpG-cytosine, except
AvaI, which contains two. Since potential causes for lack of sin-
gle-strandedness (incomplete denaturation, reannealing of com-
plementary strands, or formation of secondary structures
between complementary segments within a same strand) can occur
anywhere within the entire sequence, we selected a group of
enzymes having sites more or less evenly distributed across the en-
tire sequence. RE sites are shown in Fig. 1A, and their character-
istics are listed in Table 2. (4) REs with star activity should be
avoided. None of the enzymes chosen here have star activity,
and conditions that are known to potentially cause star activity
in certain REs (including high levels of glycerol or Mn2+, low or
high pH, low or high ionic strength, or presence of DMSO or
2-mercaptoethanol) were also avoided.
2.3.3. Multiple Restriction
Enzyme Digestion
Eighty microliters (~2 µg) of PCR products were digested with
10–20 units each, AluI, AvaI, DdeI, HhaI, and HpaII (New
England BioLabs) as per the supplier’s directives for 2.5 to 4 h.
2.4. Gel Extraction
and Subcloning
MREDdigestionswereethanolprecipitated,resuspendedinTEbuff-
erpH8.0,andelectrophoresedon3% agarosegels.Undigestedprod-
ucts (the 541-bp band) were precisely excised using a new scalpel
bladeand extracted using theSephaglas™BandPrep Kit (GE Health-
care, Uppsala, Sweden). Gel extracted products were subcloned into
Table 2
Characteristics of the MRED restriction enzymes used for RARB2
RE Site No. of non-CpG-C within RE site
A No. of sites within sequence
B A*B
AluI AGCT1 3 3
AvaI CCCGGG 2 1 2
DdeI CTNAG 1 1 1
HhaI GCGC 13 3
HpaII CCGG 1 3 3
Total 12
CpGs are underlined. Bisulfite-convertible cytosines are in boldface. Please note that these cytosines are
thymidines in the PCR-amplified product representing bisulfite converted DNA and are therefore not rec-
ognized by the RE in question
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bad, CA) vectors using T4 DNA ligase (NEB) and transformed into
competent DH5α Escherichia coli cells (Invitrogen).
2.5. Sequencing Plasmid DNAwas purified with Qiagen Maxi or Midi kits(Qiagen,
Valencia, CA) and sequenced using universal T3 and/or T7 pri-
mers. Sequencings were performed in-house or at BioS&T, Inc.,
Montreal, Canada.
2.5.1. Special
Consideration
Each sample was derived from an independent bisulfite-treated
DNA sample (i.e., only one bacterial colony was sequenced per
bisulfite reaction to ensure that sequencings were not derived
from the same PCR DNA template).
3. Results
and Discussion
In order to compare the efficiencies of the original and the mod-
ified protocols, we investigated the rates of conversion of the non-
CpG-cytosine residues within the RARB2 P2 promoter region
under analysis. These sites are not normally methylated and are,
therefore, expected to be fully converted. There are 74 non-
CpG-cytosine residues within this region (excluding those found
within regions complementary to primers JP5 and JP7): we ran-
domly set the threshold for the status of informativity to 73/74
(99%) conversions to uracil and used this threshold to distinguish
fully converted sequencings from partially converted ones. In par-
ticular, for a sample to be labeled as fully converted, it must have
reached ≥99% conversion of these non-CpG-cytosines. Upon
comparison, we found that there was a dramatic increase in the
number of informative sequencings using our modified protocol:
while only 10% of samples sequenced using the original protocol
(n=200) achieved 99% conversion of non-CpG-cytosines, 91% of
samples sequenced using the modified protocol (n=176) achieved
99% conversion (Fig. 2). It is interesting to note that the majority
of the remaining sequencings using the modified protocol were
nearly fully converted (91–98%). In contrast, nearly all sequenc-
ings using the original protocol were nearly fully unconverted
(0% and 1–10%).
The use of MRED (using AluI, AvaI, DdeI, HhaI, and
HpaII) was shown to prevent methylation bias since both meth-
ylated and unmethylated CpG-cytosines were found to be repre-
sented at all 22 CpGs in the samples analyzed (n=176; results not
shown). In order to determine whether or not there was a bias in-
troduced by the MRED modification, particularly the CpGs
106 J.J. Pappas et al.contained within the RE sites (1, 7, 15, 17, 18, 20 in Fig. 1), we
applied MRED to DNA samples previously analyzed using BGS
alone. DNA samples previously extracted from H-596 lung
adenosquamous carcinoma cells treated or not with 5-azadeoxy-
cytidine, a methylation inhibitor. Using BGS, they were found
to be fully methylated from untreated cells or fully unmethylated
following treatment with 5-azadeoxycytidine (Fig. 3). When they
were resequenced using the modified protocol, the results were
identical: 8/8 sequencings displayed complete methylation (Fig.
3, top) or complete demethylation (Fig. 3, bottom) at all 20 in-
formative sites. This clearly demonstrates that the introduction of
the MRED step does not introduce a bias at any of the 20 infor-
mative sites.
Using the BGS protocol (1) in over 400 sequencings, even
with some modifications, we found that incomplete cytosine to
uracil conversion and DNA degradation formed insurmountable
challenges. In a first effort, numerous attempts to reduce the rate
of target DNA degradation were made, including: (1) increasing
the amount of genomic DNA from 1 to 10 µg; (2) decreasing the
duration of the bisulfite conversion reaction (15); (3) incorporat-
ing up to 5 µg salmon sperm DNA; or (4) using agarose beads
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0% 1-10% 11-90% 91-98% 99-100%
BGS BGS-MRED
Fig. 2. Rates of nucleotide conversion using the original or the modified
protocols. The conversion status of 74 non-CpG-cytosine residues of the
RARB2 P2 promoter was analyzed following conversion using the stan-
dard BGS protocol (blue bars) or the MRED modification (red bars). Clones
were sequenced and grouped according to the percentage of converted
cytosine residues. Results show an increase in the frequency of cytosine
to uracil conversion using our modified protocol. While only 10% of sam-
ples sequenced using the original protocol (n=200) achieved 99% con-
version of non-CpG-cytosines, 91% of samples sequenced using the
modified protocol (n=176) achieved 99% conversion. The threshold for
the status of informativity was randomly set to 73/74 (99%) conversions
to uracil, and this threshold was used to distinguish fully converted
sequencings from partially converted ones.
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radation. In addition, the absence of PCR products could not be
associated with any one factor (it was variable and unpredictable).
In a second effort, numerous attempts to increase the rate of
cytosine to uracil conversion were made, including: (1) digesting
the genomic DNA with an endonuclease such as PstIt oc r e a t e
smaller fragments containing the target sequence thereby reduc-
ing the possibility for regional double strand formation (24); (2)
denaturing the genomic DNA in an alkaline solution prior to
BGS treatment, thereby beginning the BGS protocol with fully
denatured DNA; (3) incubating the bisulfite reactions at 95°C
(24) every 3 h, thereby aiming to maintain complete DNA dena-
turation; (4) reducing the DNA quantity to as little as 100 ng
(13); (5) increasing the sodium bisulfite concentration (6 M)
(15), (6) using high-speed BGS (9 M sodium bisulfite for
20 min at 90°C or 40 min at 70°C) (19), (7) using a lower incu-
bation temperature, such as 50°C (15), to increase the extent of
cytosine conversion and/or to reduce the annealing of single-
stranded DNA sequences during treatment; (8) monitoring the
pH of the solutions to prevent incomplete desulfonation of pyrim-
idine residues, which may inhibit DNA polymerases, leading to
unsuccessful PCR amplifications (12); (9) changing PCR exten-
sion time; (10) annealing temperature; (11) MgCl2 concentra-
tion; (12) adding dimethyl sulfoxide to inhibit secondary
structure formation (26). In all cases, PCR amplifications were
H-596 + 5azaC  
H-596  
BGS 
BGS-MRED 
BGS 
BGS-MRED 
Fig. 3. Schematic representation of the methylation analyses at the 22
CpG sites within the RARB2 P2 promoter in H-596 cells. Top DNA from un-
treated H-596 cells; Bottom H-596 cells following 5-azadeoxycytidine
treatment (fully demethylated). Each sample was derived from an inde-
pendently bisulfite-treated DNA sample (only one bacterial colony is se-
quenced per bisulfite reaction to ensure that sequencings are not derived
from the same PCR DNA template). Boxes represent CpG sites. Solid box
methylated; empty box not methylated; hatched box status unavailable.
108 J.J. Pappas et al.once again unpredictable, and when they were productive, none
of these modifications increased the rate of occurrence of fully
converted samples following BGS above 0–10%. Different primers
were also designed, including fully nested as opposed to semi-
nested primers as was the case here, to no avail.
Such resistance to deamination is a frequent characteristic of
RARB2 (unpublished observation, Dr. Michael Trus, Juravinski
Cancer Center, Hamilton, Ontario) and is not unique to RARB2
(e.g., (27–29)). Although high GC content has previously been
suggested to cause incomplete conversion (30), the 541-bp re-
gion we targeted has a GC content of 51%, 4% lower than that
characterizing most CpG islands or promoters (31).
RARB2 DNA methylation has been shown to be correlated
with RARB2 gene inactivation (32–38), and treatment with a
methyltransferase inhibitor, 5-azadeoxycytidine, has been shown
to be correlated with demethylation of exonic sequences and reacti-
vationofgeneexpression(32,34,37,39).However,fewstudieshave
analyzed the detailed methylation pattern of the promoter region
(33,40–42), andtoourknowledge, studieshavenotanalyzedisolat-
ed alleles by sequencing only one subclone per bisulfite conversion
reaction (see Section 2.5.1). The vast majority of studies have used
methylation-specific PCR, pooling potentially mixed populations
ofallelestogether,aspreviouslydescribedinref.(38),andnotallow-
ing the direct assessment of cytosine to uracil conversion.
To our knowledge, this is the first report of a RE-based
method to improve the BGS protocol. This modified protocol
is not related to techniques in which RE digestion is used to re-
veal and/or quantify DNA methylation-dependent sequence dif-
ferences in PCR-amplified bisulfite-treated DNA (43)o rw i t h
techniques in which methylation-dependent retention of preex-
isting sites, such as BstUI (CGCG; following bisulfite-induced
sequence conversion), are exploited to quantify DNA methyla-
tion at specific loci, such as in the combined bisulfite restriction
analysis (4). These techniques focus on specific CpG sites and
are based on the assumption that conversion is complete. In
contrast, the present protocol was designed to retain the fine
resolution analysis capability of the original BGS protocol. It
does so by digesting incompletely converted DNA molecules
in the resulting mixed PCR population. Conversion efficiency
is not assumed to be 100% but rather is measured directly for
every sample.
We hope that studies requiring fine resolution methylation
analyses, such as those investigating the various allelic populations
within a cell sample and those in which BGS-associated degrada-
tion and inefficient conversion impede research progress, will ben-
efit from using this modified protocol, especially given the
growing need for protocols capable of interrogating the methyla-
tion status at the nucleotide level (e.g., allele-specific methylation)
Protocol for Bisulfite Genomic Sequencing of Difficult Samples 109and the growing interest in protocols providing internal quality
control parameters. The guidelines for selecting REs are straight-
forward and may be used for the methylation analysis of any gene.
This method requires the addition of only one step, MRED, to
the original protocol, adding only 4 h to the 3-day BGS process.
While RE selection may be time consuming for some sequences,
the same combination of RE may be used for all subsequent
sequencings.
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